Ratings by Barclays (Lukas Shumway)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/16/2026 | Cellectis | CLLS | Downgrade | Underweight (Overweight) |
1.83 (0.97) |
-46.99% | Details | |
| 9/3/2026 | Alpha Tau Medical Ltd. | DRTS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/4/2026 | Alpha Tau Medical Ltd. | DRTS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2026 | Sutro Biopharma | STRO | New Coverage | Overweight (N/A) |
27.38 (10.79) |
-60.59% | Details | |
| 5/28/2026 | Immunome Inc. | IMNM | New Coverage | Overweight (N/A) |
21.91 (18.00) |
-17.85% | Details | |
| 5/28/2026 | Cellectis | CLLS | New Coverage | Overweight (N/A) |
3.67 (1.83) |
-50.14% | Details | |
| 5/28/2026 | Alpha Tau Medical Ltd. | DRTS | New Coverage | Overweight (N/A) |
10.37 (13.48) |
29.99% | Details |
